<DOC>
	<DOCNO>NCT01666678</DOCNO>
	<brief_summary>The purpose current trial evaluate bioavailability single oral dose naproxen sodium 440 mg DPH HCL 50 mg fast feed condition currently market single ingredient product contain naproxen sodium ( 2 x AleveÂ® 220 mg tablet ) DPH HCL ( 2 Allergy Relief x 25 mg tablet ) fast condition .</brief_summary>
	<brief_title>Compare Pharmacokinetic ( PK ) Profiles Naproxen Sodium , Diphenhydramine Hydrochloride , Naproxen Sodium Diphenhydramine Hydrochloride Combination</brief_title>
	<detailed_description />
	<mesh_term>Diphenhydramine</mesh_term>
	<mesh_term>Promethazine</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<criteria>Health , ambulatory male female subject 18 55 year age inclusive Body Mass Index ( BMI ) approximately 18 30 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) Results screen clinical laboratory test within normal range consider clinically significant Principal Investigator Sponsor Female subject childbearing potential must use medically acceptable form birth control least 1 month prior screen ( 3 month oral contraceptive ) , e.g. , oral patch contraceptive , intrauterine device , DepoProvera , double barrier negative pregnancy test Screening Day 0 Dosing Period . Female subject non childbearing potential must amenorrheic least 2 year hysterectomy and/or bilateral oophorectomy History hypersensitivity aspirin ( ASA ) , naproxen sodium , NSAIDs , acetaminophen , DPH HCL , similar pharmacological agent component product History hypersensitivity food product standardize breakfast consume food/beverage item contain standardize breakfast Have take ASA , ASAcontaining product , acetaminophen NSAID ( OTC prescription ) 7 day prior dose Dosing Periods , trial treatment Use overthecounter prescription medication ( except acceptable form birth control ) within 10 day prior dose throughout trial , unless opinion Investigator , medication interfere trial procedure , data integrity , compromise safety subject Recently ( past 30 day ) plan surgery , invasive procedure , tattoos piercings trial 12 week treatment Loss blood excess 500 ml within 56 day first dose trial treatment ( e.g. , donation , plasmapheresis injury ) History gastrointestinal bleeding perforation , relate previous NSAID therapy active history recurrent peptic ulcer/hemorrhage ( two distinct episode proven ulceration bleeding ) Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic disease malignancy Smokers currently consume type tobacco product ( ) include smoke cessation nicotinecontaining product ( e.g. , nicotine patch , nicotine gum ) Have take vitamin herbal supplement within 7 day prior dose refuse refrain use trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Bioequivalence</keyword>
</DOC>